EC
ACAD icon

EntryPoint Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

EntryPoint Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$285K Buy
12,819
+2,474
+24% +$59.1K 0.08% 487
2025
Q4 		$276K Hold
10,345
– – 0.11% 397
2025
Q3 		$221K Buy
10,345
+804
+8% +$19K 0.09% 510
2025
Q2 		$206K Buy
+9,541
New +$177K 0.1% 472
2025
Q1 		– Sell
-26,022
Closed -$478K – 655
2024
Q4 		$478K Buy
26,022
+15,052
+137% +$243K 0.2% 122
2024
Q3 		$169K Buy
10,970
+3,544
+48% +$59.1K 0.1% 503
2024
Q2 		$121K Buy
7,426
+2,711
+57% +$43.8K 0.18% 228
2024
Q1 		$87.2K Sell
4,715
-994
-17% -$24.6K 0.08% 498
2023
Q4 		$179K Buy
+5,709
New +$136K 0.17% 122

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return